BioSpace News Archive

McCann Health today was named to Ad Age’s 2019 “Best Places to Work” list, ranking ninth among all North American ad agencies, ad tech firms, media companies and marketing companies with more than 200 employees

FDNA, a leader in artificial intelligence and precision medicine, in collaboration with a team of influential scientists and researchers published a milestone study on the use of facial analysis in detecting genetic disorders.

The top-ranked orthopedic hospital in the U.S. and a leading global medical device manufacturer from Europe today announced the formation of the first provider-based additive manufacturing 3D printing facility for custom complex implants.

With rising drug prices and low patient response rates, Scipher Medicine is bringing precision medicine to autoimmune diseases by ensuring patients are prescribed optimal treatment from day one while avoiding side effects and the billions of dollars that payers and patients waste each year on ineffective treatments.

ChanceLight, one of the nation’s leading providers of Applied Behavior Analysis (ABA) therapy — widely recognized as the most effective, evidence-based treatment for autism — announced today it will increase its number of Georgia clinics to 13 by mid-summer 2019.

Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has achieved a significant year-end milestone of monitoring over 40,000 patients driven by rapid adoption of the Carnation Ambulatory Monitor (“CAM™"), the world’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

Biological Dynamics today announced the company will present at the Biotech Showcase™ 2019 conference, taking place during the annual J.P. Morgan Healthcare Conference on January 7-9 at the Hilton San Francisco Union Square.

Empirical Bioscience, a privately-held developer and manufacturer of enzymes, polymerases, and reagents for Molecular Biology applications, announced that it has achieved ISO 13485:2016 certification for Medical Device and Quality Management Systems, this is an upgrade from their ISO 13485:2003 certificate.

The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850

Rexgenero, a clinical-stage regenerative medicine company developing advanced cell-based therapies with a focus on Critical Limb Ischemia (CLI), today announces that its lead product REX-001 has been selected as one of only 14 products to be included in the EU Network for Health Technology Assessment (EUnetHTA) Prioritisation list (EPL) for Joint Assessment.